Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis. Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling Source: Eur Respir J 2012; 39: 1537-1538 Year: 2012
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019 Year: 2020
Evaluation of patient adherence to tuberculosis treatment by measuring drug metabolites in urine Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Lack of penetration of amikacin into saliva of tuberculosis patients Source: Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017 Year: 2018
Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001
Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Clinical pharmacology study of a new tobramycin solution for nebulisation Source: Eur Respir J 2005; 26: Suppl. 49, 729s Year: 2005
Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis Source: Virtual Congress 2020 – Tuberculosis: part 1 Year: 2020
Plasma DNA concentration and integrity measurement for NSCLC diagnostics and radical therapy effectiveness monitoring Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
Influence of a combination therapy versus steroid monotherapy on FeNO Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
The role of serum rifampicin level on antituberculosis treatment outcome Source: Eur Respir J 2006; 28: Suppl. 50, 848s Year: 2006
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
Substantial time reduction in diagnosis of Mycobacterium tuberculosis rifampicin and isoniazid resistance by the application of a DNA strip hybridization assay in clinical samples Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012
Comparison of methods for assessment of physical activity level in daily life in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 666s Year: 2004
Long-term omalizumab treatment – do drug concentration levels count? Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015